Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study
…, AVM Garcia, DE Angelini, S Mazzoni… - British Journal of …, 2021 - Wiley Online Library
The IMPEDE VTE score has recently emerged as a novel risk prediction tool for venous
thromboembolism (VTE) in multiple myeloma (MM). We retrospectively reviewed 839 patients …
thromboembolism (VTE) in multiple myeloma (MM). We retrospectively reviewed 839 patients …
[HTML][HTML] Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice
Simple Summary Multiple myeloma is an incurable hematologic malignancy arising from
terminally differentiated B-cells. Over the last decade, advancements in therapeutics have …
terminally differentiated B-cells. Over the last decade, advancements in therapeutics have …
Diagnostic and treatment strategies for AL amyloidosis in an era of therapeutic innovation
Despite significant progress and improving outcomes in the management of plasma cell
disorders, AL amyloidosis remains diagnostically and therapeutically challenging for clinicians …
disorders, AL amyloidosis remains diagnostically and therapeutically challenging for clinicians …
Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients
…, J Valent, J Khouri, C Samaras, S Mazzoni… - Critical Reviews in …, 2022 - Elsevier
There is increasing evidence regarding the role of various maintenance therapy (MT) strategies
after initial induction to treat newly diagnosed transplant-ineligible patients with MM. We …
after initial induction to treat newly diagnosed transplant-ineligible patients with MM. We …
[HTML][HTML] Role of Palliative Care in the Supportive Management of AL Amyloidosis—A Review
…, D Dima, M Schlögl, A McDonald, S Mazzoni… - Journal of Clinical …, 2024 - mdpi.com
Light chain amyloidosis is a plasma–cell disorder with a poor prognosis. It is a progressive
condition, causing worsening pain, disability, and life-limiting complications involving multiple …
condition, causing worsening pain, disability, and life-limiting complications involving multiple …
Novel high–risk acute myeloid leukemia subgroup with ERG amplification and Biallelic loss of TP53
CA Schandl, S Mazzoni, I Znoyko, GJ Nahhas… - Cancer Genetics, 2023 - Elsevier
ETS-related gene (ERG) amplification, observed in 4–6% of acute myeloid leukemia (AML),
is associated with unfavorable prognosis. To determine coincident effects of additional …
is associated with unfavorable prognosis. To determine coincident effects of additional …
Tumor lysis syndrome in anti-androgen-treated metastatic prostate cancer
S Mazzoni - International urology and nephrology, 2016 - Springer
Accepted: 7 July 2016/Published online: 14 July 2016© Springer Science+ Business Media
Dordrecht 2016 because urinary alkalinization can further decrease ionized calcium and …
Dordrecht 2016 because urinary alkalinization can further decrease ionized calcium and …
Risk of Venous Thromboembolism in Multiple Myeloma Patients During the Immediate Peri-Autologous Hematopoietic Cell Transplantation Phase
Venous thromboembolism (VTE) is a serious complication commonly experienced in cancer
patients. Incidence of VTE typically brings poor prognosis as it represents the second most …
patients. Incidence of VTE typically brings poor prognosis as it represents the second most …
Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma
Introduction The advent of novel therapies over the last decade, including proteasome inhibitors,
immunomodulators, and monoclonal antibodies, has drastically improved the outcomes …
immunomodulators, and monoclonal antibodies, has drastically improved the outcomes …
A novel risk assessment metric for antimyeloma therapies and drug interactions.
…, F Anwer, B Faiman, L Williams, SA Mazzoni… - 2023 - ascopubs.org
e24082 Background: New treatments for multiple myeloma (MM) improved both the clinical
course and survival. These differ in their mode of action, safety profile, and adverse events (…
course and survival. These differ in their mode of action, safety profile, and adverse events (…